1145983-10-3

Upstream product

• 75-15-0 carbon disulfide 
• 146924-91-6 (-)-cis-(3S,4R)-3-hydroxy-1-(4-methoxyphenyl)-4-phenyl-2-azetidinone 
• 74-88-4 methyl iodide 
• 783-08-4 [4-(benzylideneamino)phenyl]methanol 
• 100-52-7 benzaldehyde 
• 104-94-9 4-methoxy-aniline 
• 186613-02-5 cis-1-p-methoxyphenyl-3-acetoxy-4-phenylazetidin-2-one 

Downstream Products

• 162993-22-8 (S)-1-(4-methoxy-phenyl)-4-phenyl-azetidin-2-one 
• 37088-64-5 (S)-4-phenyl-2-azetidinone 
• 1067647-06-6 (S)-2-oxo-4-phenyl-azetidine-1-carboxylic acid tert-butyl ester 
• 718611-17-7 S-(3-hydroxy-1-phenyl-propyl)-carbamic acid tert-butyl ester 
• 82769-76-4 (S)-3-amino-3-phenylpropanol 

Relevant academic research and scientific papers

An efficient formal synthesis of (S)-dapoxetine from enantiopure 3-hydroxy azetidin-2-one

An efficient formal synthesis of S-(+) dapoxetine starting from 3-hydroxy azetidin-2-one is described. The intermediate (S)-3-(dimethyl amino)-3-phenylpropan-1-ol was synthesized in enantiopure form starting with 3-hydroxy azetidin-2-one in seven steps.

Process for preparation of enantiomerically pure S-(+)-N, N-dimethyl-a-[2-(naphthalenyloxy)ethyl] benzenemethanamine

The present invention relates to improved, efficient process for the preparation of enantiomerically pure S-(+)-N,N-dimethyl-a-[2-(naphthalenyloxy)ethyl] benzenemethanamine and pharmaceutically acid addition salts thereof. The present invention particularly provides a process for preparation of (3S, 4R)-3-hydroxy-1-(4-methoxyphenyl)-4-phenylazetidin-2-one useful as a key intermediate for preparation of (s)-dapoxetine.